Natco Pharma Ltd (BOM:524816) reports a 35.3% revenue increase and 83% profit growth, while navigating future market uncertainties and regulatory challenges.

Hyderabad: NATCO Pharma Limited, an Indian pharmaceutical company, has announced the approval of its Abbreviated New Drug Administration (ANDA) for Everolimus tablets for oral suspension (TFOS), 2mg, ...

ANDA for Everolimus tablets for oral suspension (TFOS) of strengths 2mg, 3mg and 5mg, Natco Pharma said in a regulatory filing. (Image: Representational/Pixabay) The approval is for the Abbreviated ...

Natco Pharma Ltd has achieved a significant milestone with the approval from the US health regulator for its generic version of Everolimus tablets for oral suspension. This approval marks a key step ...

Natco Pharma announced approval of its ANDA for Everolimus tablets for oral suspension (TFOS), 2mg, 3mg and 5mg, a generic version of AFINITOR DISPERZ by Novartis Pharmaceutical Corporation. NATCO's ...

Natco Pharma has received US FDA approval for its generic version of Everolimus tablets for oral suspension, indicated for patients with tuberous sclerosis complex. The drug is a generic version of ...